The second most common type of cancer is cervical cancer which India stands the 5th place in the world in the context of reporting cervical cancer.
On Thursday, September 1, 2022, India will get its first-ever indigenous cervical cancer vaccines that are expected to make easy treatments for patients. The vaccine will be launched by the Serum Institute of India and the Department of Biotechnology, Government of India. The market authorization for the vaccines was given by the Drug Controller General of India (DCGI) on 12 July.
This vaccine is the country’s first Quadrivalent Human Papillomavirus vaccine (qHPV) that is expected to treat cervical cancer. Through this vaccine, the body will be protected against human papillomavirus which causes vaginal, vulvar, oral, and anal cancers apart from cervical cancer.
On July 12, Adar Poonawalla said in a tweet, “For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the #DCGI @MoHFW_INDIA for granting approval today.”
